Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase 3 1

Status

Recruiting 5Terminated 1Completed 1

Sponsor Class

INDUSTRY 4OTHER 2NIH 1

Study Type

Interventional 6Observational 1

Sponsor

Cancer Type

Genitourinary 3Head & Neck 1Breast 1

Conditions

Breast Neoplasms 1236Neoplasms 1040Carcinoma, Non-Small-Cell Lung 861Prostatic Neoplasms 692Colorectal Neoplasms 614Lung Neoplasms 578Neoplasm Metastasis 439Multiple Myeloma 425Leukemia, Myeloid, Acute 401Pancreatic Neoplasms 376Ovarian Neoplasms 364Melanoma 320Carcinoma, Hepatocellular 288Recurrence 276Squamous Cell Carcinoma of Head and Neck 275Brain Neoplasms 266Glioblastoma 247Head and Neck Neoplasms 244Stomach Neoplasms 239Carcinoma, Renal Cell 228Precursor Cell Lymphoblastic Leukemia-Lymphoma 227Lymphoma 225Triple Negative Breast Neoplasms 219Hematologic Neoplasms 209Endometrial Neoplasms 209Urinary Bladder Neoplasms 202Lymphoma, Non-Hodgkin 197Uterine Cervical Neoplasms 194Sarcoma 190Glioma 190

Interventions

enzalutamide 2darolutamide 2abiraterone 2bicalutamide 1abemaciclib 1Prednisolone 1Goserelin 1Docetaxel 1AZD5305 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Bulbo-Spinal Atrophy, X-Linked × 90 days × Clear all
NCT07190300 2026-06-03

TulmiSTAR-02

Novartis

Phase 1/2 Recruiting
181 enrolled

Bulbo-Spinal Atrophy, X-Linked

NCT04708431 2026-05-19

Androgen Receptor, Implications for Health and Wellbeing: Natural History Study of Individuals With Androgen Insensitivity

National Institutes of Health Clinical Center (CC)

Recruiting
650 enrolled

Androgen-Insensitivity Syndrome, Bulbo-Spinal Atrophy, X-Linked

NCT03437941 2026-05-15

Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Corcept Therapeutics

Phase 1/2 Terminated
39 enrolled 43 charts
Genitourinary

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT06764485 2026-05-06

rechARge

Celgene

Phase 3 Recruiting
960 enrolled
Genitourinary

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT07336446 2026-05-01

ANDROMEDA

AstraZeneca

Phase 1/2 Recruiting
300 enrolled
Genitourinary

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT05694819 2026-04-08

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

National Cancer Center Hospital East

Phase 2 Completed
57 enrolled
Head & Neck

Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT06365788 2026-04-01

ABBICAR

Universitaire Ziekenhuizen KU Leuven

Phase 2 Recruiting
53 enrolled
Breast

Bulbo-Spinal Atrophy, X-Linked, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡